Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes

Yoshito Koyanagi, Shigeo Yoshida, Yoshiyuki Kobayashi, Yuki Kubo, Muneo Yamaguchi, Takahito Nakama, Shintaro Nakao, Yasuhiro Ikeda, Yuji Ohshima, Tatsuro Ishibashi, Koh Hei Sonoda

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy. Procedures: We prospectively assessed the best-corrected visual acuity (BCVA) and central macular thickness (CMT) after IVR for 6 months. Results: There were no significant differences in the baseline BCVA and CMT between both groups. In the nonvitrectomized group (n = 15), the mean changes of BCVA and CMT from baseline to month 6 were significant (p < 0.01). In the vitrectomized group (n = 10), the improvement appeared to be slower, and the mean BCVA improvement was not significant (p = 0.5), although the mean CMT decrease was significant (p < 0.05). There were no significant differences in the mean changes of BCVA and CMT between both groups at 6 months. Conclusions: The difference in the effectiveness of IVR between both groups was not significant. IVR can be a treatment option even for vitrectomized DME eyes.

Original languageEnglish
Pages (from-to)67-73
Number of pages7
JournalOphthalmologica
Volume236
Issue number2
DOIs
Publication statusPublished - Sep 1 2016

Fingerprint

Macular Edema
Visual Acuity
Vitrectomy
Ranibizumab

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems

Cite this

Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes. / Koyanagi, Yoshito; Yoshida, Shigeo; Kobayashi, Yoshiyuki; Kubo, Yuki; Yamaguchi, Muneo; Nakama, Takahito; Nakao, Shintaro; Ikeda, Yasuhiro; Ohshima, Yuji; Ishibashi, Tatsuro; Sonoda, Koh Hei.

In: Ophthalmologica, Vol. 236, No. 2, 01.09.2016, p. 67-73.

Research output: Contribution to journalArticle

Koyanagi, Yoshito ; Yoshida, Shigeo ; Kobayashi, Yoshiyuki ; Kubo, Yuki ; Yamaguchi, Muneo ; Nakama, Takahito ; Nakao, Shintaro ; Ikeda, Yasuhiro ; Ohshima, Yuji ; Ishibashi, Tatsuro ; Sonoda, Koh Hei. / Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes. In: Ophthalmologica. 2016 ; Vol. 236, No. 2. pp. 67-73.
@article{6dfc70dbed4e48e3bd730b75c8a086c8,
title = "Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes",
abstract = "Purpose: To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy. Procedures: We prospectively assessed the best-corrected visual acuity (BCVA) and central macular thickness (CMT) after IVR for 6 months. Results: There were no significant differences in the baseline BCVA and CMT between both groups. In the nonvitrectomized group (n = 15), the mean changes of BCVA and CMT from baseline to month 6 were significant (p < 0.01). In the vitrectomized group (n = 10), the improvement appeared to be slower, and the mean BCVA improvement was not significant (p = 0.5), although the mean CMT decrease was significant (p < 0.05). There were no significant differences in the mean changes of BCVA and CMT between both groups at 6 months. Conclusions: The difference in the effectiveness of IVR between both groups was not significant. IVR can be a treatment option even for vitrectomized DME eyes.",
author = "Yoshito Koyanagi and Shigeo Yoshida and Yoshiyuki Kobayashi and Yuki Kubo and Muneo Yamaguchi and Takahito Nakama and Shintaro Nakao and Yasuhiro Ikeda and Yuji Ohshima and Tatsuro Ishibashi and Sonoda, {Koh Hei}",
year = "2016",
month = "9",
day = "1",
doi = "10.1159/000446992",
language = "English",
volume = "236",
pages = "67--73",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes

AU - Koyanagi, Yoshito

AU - Yoshida, Shigeo

AU - Kobayashi, Yoshiyuki

AU - Kubo, Yuki

AU - Yamaguchi, Muneo

AU - Nakama, Takahito

AU - Nakao, Shintaro

AU - Ikeda, Yasuhiro

AU - Ohshima, Yuji

AU - Ishibashi, Tatsuro

AU - Sonoda, Koh Hei

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Purpose: To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy. Procedures: We prospectively assessed the best-corrected visual acuity (BCVA) and central macular thickness (CMT) after IVR for 6 months. Results: There were no significant differences in the baseline BCVA and CMT between both groups. In the nonvitrectomized group (n = 15), the mean changes of BCVA and CMT from baseline to month 6 were significant (p < 0.01). In the vitrectomized group (n = 10), the improvement appeared to be slower, and the mean BCVA improvement was not significant (p = 0.5), although the mean CMT decrease was significant (p < 0.05). There were no significant differences in the mean changes of BCVA and CMT between both groups at 6 months. Conclusions: The difference in the effectiveness of IVR between both groups was not significant. IVR can be a treatment option even for vitrectomized DME eyes.

AB - Purpose: To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy. Procedures: We prospectively assessed the best-corrected visual acuity (BCVA) and central macular thickness (CMT) after IVR for 6 months. Results: There were no significant differences in the baseline BCVA and CMT between both groups. In the nonvitrectomized group (n = 15), the mean changes of BCVA and CMT from baseline to month 6 were significant (p < 0.01). In the vitrectomized group (n = 10), the improvement appeared to be slower, and the mean BCVA improvement was not significant (p = 0.5), although the mean CMT decrease was significant (p < 0.05). There were no significant differences in the mean changes of BCVA and CMT between both groups at 6 months. Conclusions: The difference in the effectiveness of IVR between both groups was not significant. IVR can be a treatment option even for vitrectomized DME eyes.

UR - http://www.scopus.com/inward/record.url?scp=84978137359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978137359&partnerID=8YFLogxK

U2 - 10.1159/000446992

DO - 10.1159/000446992

M3 - Article

C2 - 27362944

AN - SCOPUS:84978137359

VL - 236

SP - 67

EP - 73

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 2

ER -